Clinical Trial

UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Autoimmune hemolytic anemia. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
Trial Details
NCT Number NCT06920446
Lead Sponsor Zhejiang University
Collaborators: Shanghai Xiniao Biotech Co., Ltd.
Conditions Relapsed / Refractory Autoimmune Hemolytic Anemia
Enrollment 18 participants
Start Date 2025-04-03
Primary Completion 2026-04 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-04-09